Minimally Invasive Biopsy Robots Market Size, Share, and Growth Forecast, 2026 - 2033

The global minimally invasive biopsy robots market size is likely to be valued at US$0.7 billion in 2026 and is expected to reach US$1.6 billion by 2033, growing at a CAGR of 12.9% between 2026 and 2033.

Market expansion is supported by increasing demand for accurate tissue sampling, the adoption of robotic-assisted bronchoscopy, and advances in image-guided navigation. Growing lung cancer screening activity is creating opportunities to diagnose and sample small peripheral pulmonary nodules that are difficult to access using conventional techniques. Robotic-assisted biopsy systems are the leading product category, while artificial intelligence (AI), real-time imaging, and image-fusion technologies are creating additional opportunities to improve lesion localization and procedural efficiency.

Drivers - Rising Demand for Earlier Cancer Diagnosis and Accurate Tissue Sampling

The increasing use of diagnostic imaging is expanding the number of suspicious lesions that require further clinical assessment and, in selected cases, tissue confirmation. Lung cancer illustrates this opportunity, with the U.S. National Cancer Institute estimating approximately 226,650 new cases in the United States in 2025. The U.S. Centers for Disease Control and Prevention identifies low-dose computed tomography (CT) as the recommended screening test for eligible high-risk adults. Although imaging can identify suspicious pulmonary nodules, clinicians may need a biopsy to establish a diagnosis. Robotic bronchoscopy and robotic needle-positioning systems can help access difficult lesions and guide tissue sampling. For manufacturers, the commercial opportunity depends on translating screening-related diagnostic demand into procedures with reliable diagnostic performance.

Integration of Robotics, Navigation Software, and Advanced Imaging

Robotic biopsy platforms increasingly combine precise instrument control with three-dimensional imaging, anatomical mapping, and real-time navigation. These capabilities address the challenge of reaching small lesions whose actual location may differ from the position predicted by preprocedural scans. In October 2025, Intuitive Surgical announced software advancements for its Ion endoluminal system, incorporating AI throughout the navigation workflow and expanding imaging capabilities. Johnson & Johnson MedTech has also advanced its MONARCH platform with AI-powered navigation and compatibility with mobile cone-beam CT imaging. These developments demonstrate a shift from hardware-led differentiation toward integrated procedural systems. Vendors that substantiate targeting performance, improve workflow compatibility, and support clinician training may strengthen adoption among hospitals and specialist diagnostic centers.

Restraint - Capital Expenditure, Clinical Validation, and Regulatory Complexity

Robotic biopsy systems require investment in robotic platforms, imaging equipment, compatible instruments, staff training, maintenance, and clinical workflow integration. Hospitals must evaluate these costs against procedure volumes, diagnostic performance, and the availability of conventional alternatives. Lower-volume centers may struggle to justify dedicated installations, particularly when a platform requires additional imaging infrastructure or disposable instruments. Regulatory requirements can also extend commercialization timelines. In the United States, applicable devices may require Food and Drug Administration (FDA) 510(k) clearance or another authorization pathway, depending on their classification and intended use. The 510(k) pathway requires manufacturers to demonstrate substantial equivalence to a legally marketed predicate device. Manufacturers therefore face both adoption risk and regulatory execution risk, particularly when clinical evidence and hospital-level economic benefits remain limited.

Opportunities - AI-Enabled Targeting and Multimodal Image Fusion

AI-assisted navigation offers manufacturers an opportunity to combine preprocedural imaging with live procedural information to improve lesion localization and instrument positioning. Fusion workflows can incorporate CT, magnetic resonance imaging (MRI), ultrasound, fluoroscopy, or bronchoscopic imaging, depending on the procedure and system configuration. Improved visualization may help clinicians identify deviations from planned instrument trajectories and assess whether the sampling instrument has reached the intended target. Recent advancements in the Ion and MONARCH platforms demonstrate that established manufacturers are pursuing software-led upgrades alongside hardware development. Investors should evaluate these products based on clinical validation, interoperability, training requirements, and documented diagnostic performance. Systems that demonstrate measurable clinical benefits without adding excessive cost or procedural complexity may have stronger long-term adoption potential.

Expansion into Emerging Healthcare Markets and Additional Biopsy Applications

Asia Pacific provides opportunities to expand robotic biopsy adoption as hospitals invest in advanced imaging, interventional pulmonology, cancer diagnosis, and specialist treatment capacity. China, Japan, India, and selected Association of Southeast Asian Nations (ASEAN) markets differ in procurement arrangements, regulatory pathways, and affordability, creating demand for adaptable commercialization models. Manufacturers can address these differences through distributor partnerships, local clinical training, service networks, and platforms compatible with existing imaging infrastructure. Additional opportunities exist in prostate, breast, brain, liver, and kidney biopsy, although each application requires procedure-specific evidence and instruments. A practical expansion strategy is to prioritize high-volume clinical indications and specialist hospitals before broadening the product portfolio or entering lower-volume facilities.

Product Type Insights

Robotic-assisted biopsy systems are anticipated to account for approximately 54.2% of market revenue, supported by growing adoption of robotic instrument positioning, navigation software, and precision control. Intuitive Surgical's Ion system, Johnson & Johnson MedTech's MONARCH platform, and Noah Medical's Galaxy system illustrate the use of robotic bronchoscopy for sampling peripheral lung lesions. Other products include image-guided, needle-based, and vacuum-assisted robotic biopsy systems, along with instruments and accessories. Recurring demand for compatible instruments and maintenance can complement initial platform sales.

AI- and Navigation-Assisted Biopsy Devices are anticipated to be the fastest-growing product type, driven by AI-based lesion targeting, real-time guidance, and image-fusion capabilities. For example, Ion's navigation software advancements and MONARCH's AI-powered navigation demonstrate how manufacturers are integrating software with robotic systems. These technologies aim to improve targeting and procedural efficiency, although clinical adoption depends on validated performance and compatibility with existing workflows. Suppliers that demonstrate measurable benefits while controlling system costs may gain a competitive advantage.

Biopsy Application Insights

Lung Biopsy is anticipated to account for approximately 43.7% of market revenue. Demand reflects the challenge of accessing peripheral pulmonary nodules using conventional bronchoscopy. Intuitive Surgical's Ion, Johnson & Johnson MedTech's MONARCH, and Noah Medical's Galaxy systems demonstrate the application of robotic navigation to lung lesion sampling. Low-dose CT screening also supports demand for diagnostic evaluation of suspicious nodules, although not every detected lesion requires a biopsy. Other applications include breast, prostate, brain, liver, kidney, and thyroid biopsy.

Lung Biopsy and Peripheral Pulmonary Nodule Sampling are anticipated to be the fastest-growing applications, supported by screening activity and the need to reach small, difficult-to-access lesions. In May 2025, Johnson & Johnson reported that its prospective, multicenter TARGET study achieved 98.7% lesion navigation and an 83.2% diagnostic yield with the MONARCH platform. These results demonstrate the importance of clinical evidence, although outcomes may vary across settings. Prostate biopsy offers additional opportunities through robotic positioning and MRI/ultrasound fusion, while breast and neurosurgical procedures may benefit from precise image-guided targeting. Adoption will depend on application-specific validation and clinical utility.

North America Minimally Invasive Biopsy Robots Market Trends

North America is anticipated to lead the minimally invasive biopsy robots market, accounting for approximately 41.4% of global revenue. The United States benefits from advanced imaging infrastructure, specialist hospitals, medical-device innovation, and established commercialization pathways. Demand is supported by lung cancer screening and the need to sample peripheral pulmonary nodules that can be difficult to reach using conventional bronchoscopy.

United States Minimally Invasive Biopsy Robots Market Trends

The United States remains central to product development and clinical adoption because hospitals can evaluate new platforms within established specialist pulmonary programs. FDA authorization requirements, capital budgets, reimbursement, and evidence of diagnostic performance continue to influence purchasing decisions. Manufacturers that demonstrate reliable lesion access, efficient workflows, and sustainable costs per procedure are better positioned to expand adoption. The National Cancer Institute reported that the proportion of eligible U.S. adults up to date with lung cancer screening increased from 3.6% in 2010 to 18.7% in 2024. This creates opportunities for robotic bronchoscopy, although screening findings do not automatically translate into biopsy procedures. Intuitive Surgical’s Ion system, Johnson & Johnson MedTech’s MONARCH platform, and Noah Medical’s Galaxy system illustrate competition around navigation, access to peripheral lesions, and procedural precision. In March 2025, Noah Medical reported that Galaxy had reached 5,000 procedures in the United States, indicating growing clinical utilization. Johnson & Johnson’s MONARCH QUEST development also emphasized AI-powered navigation and integration with GE HealthCare’s OEC 3D mobile cone-beam CT imaging system, reinforcing the importance of combining robotics with advanced visualization.

Canada Minimally Invasive Biopsy Robots Market Trends

Canada offers opportunities through academic hospitals, specialist cancer services, and established diagnostic infrastructure. However, provincial healthcare funding and hospital procurement can influence the pace of adoption. Suppliers must demonstrate clinical value and provide training and maintenance support to justify investment in robotic systems.

Europe Minimally Invasive Biopsy Robots Market Trends

Europe is an important market, supported by specialist cancer centers, established hospital systems, and demand for less invasive diagnostic procedures. The EU Medical Device Regulation, applicable since May 2021, strengthened requirements for clinical evaluation, conformity assessment, and postmarket surveillance. These requirements influence launch timelines and investment, making regulatory readiness and clinical evidence important competitive factors.

Germany Minimally Invasive Biopsy Robots Market Trends

Germany’s advanced hospital infrastructure and medical technology expertise make it a relevant market for robotic biopsy systems. Adoption will depend on hospital investment decisions, clinical evidence, and compatibility with existing imaging and procedural equipment. Vendors offering training, maintenance, and integration support may be better positioned to secure long-term hospital contracts.

United Kingdom Minimally Invasive Biopsy Robots Market Trends

The United Kingdom offers opportunities through specialist respiratory services and cancer diagnostic pathways. Its separate medical-device regulatory framework requires manufacturers to account for applicable UK requirements alongside European Union compliance. Hospitals are likely to assess robotic platforms on diagnostic utility, workflow efficiency, and affordability.

Asia Pacific Minimally Invasive Biopsy Robots Market Trends

Asia Pacific is anticipated to be the fastest-growing regional market as healthcare systems expand specialist diagnostics and invest in advanced imaging. Growth prospects differ by country according to purchasing capacity, regulatory processes, infrastructure, and access to trained clinicians.

China Minimally Invasive Biopsy Robots Market Trends

China offers opportunities through its large healthcare system and developing domestic medical robotics industry. In November 2023, Johnson & Johnson MedTech announced regulatory approval of its MONARCH platform for bronchoscopy in China, expanding the system’s geographic reach beyond the United States. This development illustrates how regulatory authorization can open access to major hospital networks, while localization, service capability, and clinical adoption remain important for commercial expansion.

Hong Kong Minimally Invasive Biopsy Robots Market Trends

Hong Kong provides an example of commercial deployment within Asia’s specialist hospital sector. In September 2026, Noah Medical announced the first commercial procedure in Asia using its Galaxy robotic-assisted bronchoscopy system at Prince of Wales Hospital. The milestone followed earlier clinical use at the institution and indicates progress toward routine clinical integration. Galaxy’s embedded imaging and real-time targeting capabilities may appeal to centers seeking improved access to peripheral lung lesions, although broader regional adoption will depend on affordability, training, and procedural demand.

The market combines specialized robotic platform developers, established surgical technology companies, and suppliers of imaging, navigation, and biopsy instruments. Competition is particularly active in robotic bronchoscopy, where Intuitive Surgical, Johnson & Johnson MedTech, and Noah Medical have developed distinct approaches to navigation and lesion targeting. Other participants serve prostate biopsy, neurosurgical guidance, breast biopsy, and percutaneous needle procedures. The market has concentrated competition within selected applications but a broader supplier base across the overall product category. Comparable, audited market-share percentages for individual companies are not available in a consistent form because corporate filings generally do not isolate revenue for this specific market.

Leading companies emphasize navigation accuracy, imaging integration, clinical evidence, and compatibility with existing procedural infrastructure. Specialized developers differentiate through focused applications, while established medical technology companies draw on broader distribution and service networks. Common strategic priorities include recurring instrument revenue, software upgrades, clinician training, and geographic expansion. Demonstrated clinical performance and sustainable procedure economics remain essential differentiators.

Key Industry Developments

• In July 2026, AbbVie announced European Commission approval of RINVOQ (upadacitinib) for adults and adolescents aged 12 years and older with nonsegmental vitiligo who are candidates for systemic therapy.
• In October 2026, Pfizer announced positive Phase 3 results for LITFULO (ritlecitinib) in two trials involving patients with nonsegmental vitiligo.